

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS	28	Mar 20	EVENTLINE will be removed from STN
NEWS	29	Mar 24	PATDPAFULL now available on STN
NEWS	30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	31	Apr 11	Display formats in DGENE enhanced
NEWS	32	Apr 14	MEDLINE Reload
NEWS	33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	36	Apr 28	RDISCLOSURE now available on STN
NEWS	37	May 05	Pharmacokinetic information and systematic chemical names added to PHAR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:38:00 ON 11 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:38:12 ON 11 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9

DICTIONARY FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STN Note 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s pyridopyrimidine/cn

L1 0 PYRIDOPYRIMIDINE/CN

=> s pyridopyrimidine

Thomas McKenzie 05/11/2003

L2 0 PYRIDOPYRIMIDINE

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.64	9.85

FILE 'CAPLUS' ENTERED AT 09:39:49 ON 11 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 May 2003 VOL 138 ISS 20  
FILE LAST UPDATED: 9 May 2003 (20030509/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s wo200130768?/pn

L3 1 WO200130768?/PN  
(WO2001030768/PN)

=> s wo-200116114?/pn

L4 1 WO-200116114?/PN  
(WO2001016114/PN)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.86	13.71

FILE 'REGISTRY' ENTERED AT 09:40:42 ON 11 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9  
DICTIONARY FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Thomas McKenzie 05/11/2003

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=> s pyrido[2,3-d]pyrimidine/cn
L5          0 PYRIDO[2,3-D]PYRIMIDINE/CN
```

```
=> s pyrido[2,3-d]pyrimidine/cns
          140299 PYRIDO/CNS
          112135 2,3-D/CNS
          159578 PYRIMIDINE/CNS
L6          8193 PYRIDO[2,3-D]PYRIMIDINE/CNS
              ((PYRIDO(W)2,3-D(W)PYRIMIDINE)/CNS)
```

```
=> d scan cn str rid
'RID' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

```
L6  8193 ANSWERS  REGISTRY  COPYRIGHT 2003 ACS
IN  Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-2-[4-
    [[3-(2-methylpropoxy)benzoyl]amino]thioxomethyl]-1-piperazinyl]-5-oxo-
    (9CI)
MF  C26 H30 N6 O5 S
```



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
```

SQN - Protein sequence name information, includes RN

CALC - Table of calculated properties

EPROP - Table of experimental properties

PROP - EPROP and CALC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract

APPS -- Application and Priority Information

BIB -- CA Accession Number, plus Bibliographic Data

CAN -- CA Accession Number

CBIB -- CA Accession Number, plus Bibliographic Data (compressed)

IND -- Index Data

IPC -- International Patent Classification

PATS -- PI, SO

STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels

IBIB -- BIB, indented, with text labels

ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.

HELP FORMATS -- To see detailed descriptions of the predefined formats.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d scan cn str rsd


INVALID SCAN FIELD FOR FILE 'REGISTRY'

One or more of the display fields specified are not valid with DISPLAY SCAN in the current file. Enter HELP DSCAN at the arrow prompt (=>) for the list of fields that may be used when scanning the answers.

=> d cn str rsd 1 44 79

L6 ANSWER 1 OF 8193 REGISTRY COPYRIGHT 2003 ACS

CN **Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-hydroxy-1,3-dimethyl-7-(4-morpholinyl)-6-nitro- (9CI)** (CA INDEX NAME)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

#### Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C4NO	NC2OC2	6	C4NO	46.402.1	1
C4N2-C5N	NCNC3-NC5	6-6	C7N3	591.304.18	1

L6 ANSWER 44 OF 8193 REGISTRY COPYRIGHT 2003 ACS

CN **Pyrido[2,3-d]pyrimidine-2(1H)-thione, 4-amino-5,7-dimethyl- (9CI)**  
(CA INDEX NAME)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


#### Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C4N2-C5N	NCNC3-NC5	6-6	C7N3	591.304.27	1

L6 ANSWER 79 OF 8193 REGISTRY COPYRIGHT 2003 ACS

CN **Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 2-[4-[[[4-**

(butoxycarbonyl)phenyl]amino]thioxomethyl]-1-piperazinyl]-8-ethyl-5,8-dihydro-5-oxo- (9CI) (CA INDEX NAME)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

#### Ring System Data

Elemental Analysis	Elemental Sequence	Size of the Rings	Ring System Formula	Ring Identifier	RID Occurrence
EA	ES	SZ	RF	RID	Count
C6	C6	6	C6	46.150.18	1
C4N2	NC2NC2	6	C4N2	46.383.1	1
C4N2-C5N	NCNC3-NC5	6-6	C7N3	591.304.13	1

```
=> s l3 and 591.304/rid
      0 WO200130768?/PN
      (WO2001030768/PN)
      14204 591.304/RID
L7      0 L3 AND 591.304/RID

=> transfer l3
ENTER ANSWER NUMBERS, RANGES (1-), OR ?:.
ENTER DISPLAY FIELDS (TI) OR ?:rn
L8      TRANSFER L3 1- RN :      427 TERMS
L9      427 L8

=> s l9 and 591.304/rid
      14204 591.304/RID
L10     0 L9 AND 591.304/RID

=> transfer l4 1- rn
L11     TRANSFER L4 1- RN :      46 TERMS
L12     46 L11

=> s l12 and 591.304/rid
      14204 591.304/RID
```

L13 0 L12 AND 591.304/RID

=> s l12 and 591/rid  
1877036 591/RID

L14 25 L12 AND 591/RID


=> s l9 and 591/rid  
1877036 591/RID

L15 420 L9 AND 591/RID

=> d l14 cn str cbib pi

L14 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2003 ACS

CN 4(3H)-Quinazolinone, 2-[1-[[2-(dimethylamino)ethyl]amino]ethyl]-3-(4-fluorophenyl)-6-methoxy- (9CI) (CA INDEX NAME)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REFERENCE 1: 134:222723 Preparation of quinazolinones for modulating CXR3 function. Schall, Thomas J.; Dairaghi, Daniel J.; McMaster, Brian E. (Chemocentryx, Inc., USA). PCT Int. Appl. WO 2001016114 A2 20010308, 53 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US23556 20000825. PRIORITY: US 1999-PV151212 19990827.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2001016114	A2	20010308	WO 2000-US23556	20000825
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1216232	A1	20020626	EP 2000-959489	20000825
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL		

US 6559160

B1

20030506

US 2000-648329


20000825

=> d scan 114

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Decanamide, N-[1-[6-chloro-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)

MF C30 H40 Cl F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):24

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 4(3H)-Quinazolinone, 2-ethyl-3-(4-fluorophenyl)- (9CI)

MF C16 H13 F N2 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS


IN Decanamide, N-[1-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)

MF C31 H44 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-6-methyl-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
 MF C31 H43 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Decanamide, N-[1-[6-amino-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
 MF C30 H42 F N5 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-  
dihydro-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C30 H41 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-  
dihydro-6-nitro-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C30 H40 F N5 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-6-(2-phenylethyl)-2-quinazolinyl]ethyl]- (9CI)  
 MF C38 H49 F N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 4H-3,1-Benzoxazin-4-one, 2-ethyl- (7CI, 8CI, 9CI)  
 MF C10 H9 N O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Decanamide, N-[1-[6-chloro-3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)

MF C31 H43 Cl N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-6-(phenylethynyl)-2-quinazolinyl]ethyl]- (9CI)

MF C38 H45 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS


IN 4(3H)-Quinazolinone, 2-[1-[2-(dimethylamino)ethyl]amino]ethyl]-3-(4-fluorophenyl)-6-methoxy- (9CI)

MF C21 H25 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[1-[3,4-dihydro-6-methoxy-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C32 H46 N4 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-6-phenyl-2-quinazolinyl]ethyl]- (9CI)  
MF C36 H45 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-(1-bromoethyl)-3-(4-fluorophenyl)-6-methoxy- (9CI)  
MF C17 H14 Br F N2 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-6-methoxy-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C31 H43 F N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[5-fluoro-3-(4-fluorophenyl)-  
3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C30 H40 F2 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-ethyl-3-(4-fluorophenyl)-6-methoxy- (9CI)  
MF C17 H15 F N2 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-  
quinazolinyl]ethyl]-N-[2-(1-piperidinyl)ethyl]- (9CI)  
MF C33 H45 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-6,7,8-trimethoxy-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C33 H47 F N4 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[1-[2-(dimethylamino)ethyl]amino]ethyl]-3-(4-fluorophenyl)- (9CI)  
MF C20 H23 F N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[1-[decyl[2-(dimethylamino)ethyl]amino]ethyl]-3-(4-fluorophenyl)- (9CI)  
MF C30 H43 F N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[2-(dimethylamino)ethyl]-N-[1-[3-(4-fluorophenyl)-3,4-dihydro-6-iodo-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C30 H40 F I N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-(1-bromoethyl)-3-(4-fluorophenyl)- (9CI)  
MF C16 H12 Br F N2 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L14 25 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Decanamide, N-[3-(dimethylamino)propyl]-N-[1-[3-(4-fluorophenyl)-3,4-  
dihydro-4-oxo-2-quinazolinyl]ethyl]- (9CI)  
MF C31 H43 F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d l15 cn str cbib pi

L15 ANSWER 1 OF 420 REGISTRY COPYRIGHT 2003 ACS  
CN 1-Naphthalenecarboxamide, N-[1-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-  
quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REFERENCE 1: 136:53759 Preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors. Finer, Jeffrey T.; Bergnes, Gustav; Feng, Bainian; Smith, Whitney W.; Chabala, John C.; Morgans, David J., Jr. (Cytokinetics, Inc., USA). PCT Int. Appl. WO 2001098278 A1 20011227, 179 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US13901 20010427. PRIORITY: US 2000-PV213104 20000621; US 2000-699047 20001024. PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2001098278	A1	20011227	WO 2001-US13901	20010427
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6545004	B1	20030408	US 2000-699047	20001024
	JP 2003048881	A2	20030221	JP 2002-156766	20001026
	EP 1296959	A1	20030402	EP 2001-932769	20010427
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	NO 2002006172	A	20030220	NO 2002-6172	20021220

REFERENCE 2: 134:326543 Methods and compositions utilizing quinazolinones as KSP kinesin modulators. Finer, Jeffrey T.; Bergnes, Gustave; Feng, Bainian; Smith, Whitney W.; Chabala, John C. (Cytokinetics, Inc., USA). PCT Int. Appl. WO 2001030768 A1 20010503, 168 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,

MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.

(English). CODEN: PIXXD2. APPLICATION: WO 2000-US29585 20001026.

PRIORITY: US 1999-PV198253 19991027; US 2000-PV213104 20000621.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001030768	A1	20010503	WO 2000-US29585	20001026
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000015110	A	20020702	BR 2000-15110	20001026
EP 1226129	A1	20020731	EP 2000-976656	20001026
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003048881	A2	20030221	JP 2002-156766	20001026
JP 2003512461	T2	20030402	JP 2001-533122	20001026
NO 2002001907	A	20020607	NO 2002-1907	20020423

=> d scan l15

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Benzoic acid, 4-[[ (2-aminoethyl) [1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]methyl]-, methyl ester (9CI)

MF C29 H31 Cl N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS


IN 4(3H)-Quinazolinone, 2-[1-[ (2-aminoethyl) [ (2,5-difluorophenyl)methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI)

MF C27 H27 Cl F2 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[1-[(2-aminoethyl)[(2,4-difluorophenyl)methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI)  
MF C27 H27 Cl F2 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3,5-dimethoxy- (9CI)  
MF C31 H36 N4 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 4-bromo-N-[[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C27 H27 Br N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[3,4-dihydro-3-(2-methoxyethyl)-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)- (9CI)  
MF C26 H31 F3 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C29 H30 Cl2 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)  
 MF C30 H30 Cl F3 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylsulfinyl)propyl]-4-methyl- (9CI)  
 MF C30 H33 Cl N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 4-bromo-N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C29 H29 Br F2 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-(trifluoromethyl)- (9CI)  
MF C31 H32 Cl F3 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)  
MF C32 H35 Cl N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI)  
MF C28 H28 Br Cl N4 O2





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-(3-methylphenyl)- (9CI)  
MF C31 H27 N3 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 4-bromo-N-[1-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C28 H28 Br Cl N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 4-butyl-N-[1-(7-chloro-3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C27 H35 Cl N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Butanamide, 4-chloro-N-[1-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-ethyl- (9CI)  
MF C23 H25 Cl2 N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(2-methoxyethyl)-4-methyl- (9CI)  
MF C29 H31 N3 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[(1S)-1-amino-2-methylpropyl]-7-chloro-3-(phenylmethyl)- (9CI)  
MF C19 H20 Cl N3 O



Absolute stereochemistry.

Thomas McKenzie 05/11/2003




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, 4-bromo-N-[1-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C28 H28 Br2 N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzamide, N-[1-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI)  
MF C27 H26 Br F N4 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 2-Propenamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-3-phenyl-N-propyl- (9CI)  
 MF C29 H29 N3 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Benzonitrile, 4-[[ (3-aminopropyl) [1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]methyl]- (9CI)  
 MF C29 H30 Cl N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[1-[(2-aminoethyl)[(2,3-  
difluorophenyl)methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI)  
MF C27 H27 Cl F2 N4 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 4(3H)-Quinazolinone, 2-[1-[(2-aminoethyl)[(3,5-  
dimethylphenyl)methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI)  
MF C29 H33 Cl N4 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 420 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1,3-Benzodioxole-5-carboxamide, N-[1-(7-chloro-3-ethyl-3,4-dihydro-4-oxo-2-  
quinazolinyl)propyl]-N-[2-(dimethylamino)ethyl]- (9CI)  
MF C25 H29 Cl N4 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

21.94

95.55

STN INTERNATIONAL LOGOFF AT 09:52:54 ON 11 MAY 2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN

Thomas McKenzie 05/11/2003

NEWS 13 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 14 Nov 25 More calculated properties added to REGISTRY  
NEWS 15 Dec 04 CSA files on STN  
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 17 Dec 17 TOXCENTER enhanced with additional content  
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 20 Feb 13 CANCERLIT is no longer being updated  
NEWS 21 Feb 24 METADEX enhancements  
NEWS 22 Feb 24 PCTGEN now available on STN  
NEWS 23 Feb 24 TEMA now available on STN  
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 25 Feb 26 PCTFULL now contains images  
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 27 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 28 Mar 20 EVENTLINE will be removed from STN  
NEWS 29 Mar 24 PATDPAFULL now available on STN  
NEWS 30 Mar 24 Additional information for trade-named substances without  
structures available in REGISTRY  
NEWS 31 Apr 11 Display formats in DGENE enhanced  
NEWS 32 Apr 14 MEDLINE Reload  
NEWS 33 Apr 17 Polymer searching in REGISTRY enhanced  
NEWS 34 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS  
NEWS 35 Apr 21 New current-awareness alert (SDI) frequency in  
WPIDS/WPINDEX/WPIX  
NEWS 36 Apr 28 RDISCLOSURE now available on STN  
NEWS 37 May 05 Pharmacokinetic information and systematic chemical names  
added to PHAR  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:07:39 ON 11 MAY 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

Thomas McKenzie 05/11/2003

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:07:47 ON 11 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9  
DICTIONARY FILE UPDATES: 9 MAY 2003 HIGHEST RN 513416-44-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>.



=>

Uploading C:\Program Files\Stnexp\Queries\10015532.str



\* 12 \*

14  
||  
13  
\*



chain nodes :  
11 12 13 14 19 20  
ring nodes :

1 2 3 4 5 6 7 8 9 10  
chain bonds :  
8-11 9-19 13-14 19-20  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10  
exact/norm bonds :  
4-7 5-10 7-8 8-9 8-11 9-10 13-14 19-20  
exact bonds :  
9-19  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 13:CLASS 14:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> s 11

SAMPLE SEARCH INITIATED 10:08:03 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 92 TO ITERATE

100.0% PROCESSED 92 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1265 TO 2415  
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN Benzeneacetamide, N-(2-ethoxyethyl)-N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-  
dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-(trifluoromethyl)- (9CI)  
MF C30 H31 F3 N4 O4

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full

FULL SEARCH INITIATED 10:08:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2262 TO ITERATE

100.0% PROCESSED 2262 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

L3 21 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 10:08:31 ON 11 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 May 2003 VOL 138 ISS 20

FILE LAST UPDATED: 9 May 2003 (20030509/ED)

This file contains CAS Registry Numbers for easy and accurate

Thomas McKenzie 05/11/2003

substance identification.

=> s 13

L4 2 L3

=> d 1-2 cbib pi hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

2002:813938 Document No. 137:337907 Preparation of N-

(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions. Medina, Julio C.; Johnson, Michael G.; Li, An-Rong; Liu, Jiwen; Huang, Alan Xi; Zhu, Liusheng; Marcus, Andrew P. (Tularik Inc., USA). PCT Int. Appl. WO 2002083143 A1 20021024, 205 pp.

DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2001-US47850 20011211. PRIORITY: US 2000-PV255241 20001211; US 2001-PV296499 20010606.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002083143	A1	20021024	WO 2001-US47850	20011211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002169159	A1	20021114	US 2001-15532	20011211
US 2003069234	A1	20030410	US 2002-164690	20020606
US 2003055054	A1	20030320	US 2002-231895	20020829


IT 473720-05-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(CXCR3 antagonist; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473720-05-7 CAPLUS

CN Benzeneacetamide, N-[1-[3,4-dihydro-4-oxo-3-[4-(2,2,2-trifluoroethoxy)phenyl]pyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




IT 473718-93-3P 473719-41-4P 473719-45-8P  
473719-49-2P 473719-90-3P 473719-95-8P  
473720-16-0P 473720-18-2P 473720-19-3P  
473720-20-6P 473720-21-7P 473720-22-8P  
473720-23-9P 473720-24-0P 473720-25-1P  
473720-26-2P 473720-30-8P 473722-68-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CXCR3 antagonist; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473718-93-3 CAPLUS


CN [1,1'-Biphenyl]-4-acetamide, N-(2-ethoxyethyl)-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 473719-41-4 CAPLUS

CN Benzeneacetamide, N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473719-45-8 CAPLUS

CN Benzeneacetamide, N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473719-49-2 CAPLUS


CN Benzeneacetamide, N-(2-ethoxyethyl)-N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473719-90-3 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-3-(trifluoromethoxy)- (9CI)  
(CA INDEX NAME)



RN 473719-95-8 CAPLUS


CN Benzeneacetamide, N-[[2-(dimethylamino)-3-pyridinyl]methyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473720-16-0 CAPLUS


Thomas McKenzie 05/11/2003

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-[2-(4-morpholinyl)ethyl]-4-(trifluoromethoxy)-  
(9CI) (CA INDEX NAME)




RN 473720-18-2 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-cyanophenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)




RN 473720-19-3 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(1H-indol-3-ylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473720-20-6 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-[2-(4-methyl-1-piperazinyl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 473720-21-7 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(2-thienylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473720-22-8 CAPLUS


CN Benzeneacetamide, N-[2-[(1,1-dimethylethyl)methylamino]ethyl]-N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 473720-23-9 CAPLUS

CN Benzeneacetamide, N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473720-24-0 CAPLUS

CN Benzeneacetamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473720-25-1 CAPLUS

CN Benzeneacetamide, N-[(2-cyclopropyl-5-pyrimidinyl)methyl]-N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473720-26-2 CAPLUS

CN Benzeneacetamide, N-[(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-[[6-(1-pyrrolidinyl)-3-pyridinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473720-30-8 CAPLUS


CN Benzeneacetamide, N-[(1S)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 473722-68-8 CAPLUS

CN Benzeneacetamide, N-[1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-4-fluoro-N-(3-pyridinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 473720-93-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-(heteroarylalkyl)acylamides as CXCR3 antagonists for treatment of inflammatory or immune conditions)

RN 473720-93-3 CAPLUS

CN Carbamic acid, [(1R)-1-[3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl](3-pyridinylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

2001:208250 Document No. 134:252352 Preparation of 3-aryl-2-aryllureidoalkylquinazolin-4-ones and related compounds as mediators of hedgehog signaling pathways.. Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Oivin M.; Price, Stephen; Rubin, Lee D. (Curis, Inc., USA). PCT Int. Appl. WO 2001019800 A2 20010322, 177 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US25461 20000915. PRIORITY: US 1999-PV154526 19990916; US 1999-PV159412 19991014; US 1999-PV162899 19991101.


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019800	A2	20010322	WO 2000-US25461	20000915
	WO 2001019800	A3	20011206		
	WO 2001019800	C2	20021003		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216234	A2	20020626	EP 2000-963551	20000915
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003509414	T2	20030311	JP 2001-523380	20000915
	US 6545005	B1	20030408	US 2000-663835	20000915

IT 330796-36-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 3-aryl-2-aryllureidoalkylquinazolin-4-ones and related compds. as mediators of hedgehog signaling pathways)

RN 330796-36-6 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-methyl-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.93

156.29

STN INTERNATIONAL LOGOFF AT 10:11:04 ON 11 MAY 2003